
Cohero Health, a company focused on developing connected health tools and technologies to improve respiratory care, has received the FDA clearance for its mobile spirometer.
According to the developer, the handheld, wireless spirometer measures critical lung function metrics with the same precision as clinical-grade spirometers.
Advertisement
The mobile spirometer pairs with a smartphone or tablet, enabling real-time measurement and reporting.
The device integrates with Cohero Health's mobile asthma and Chronic obstructive pulmonary disease (COPD) management platform. The device includes bluetooth sensors that attach to maintenance and rescue medication and mobile apps that track medication usage, motivate, remind, and reward patients for improved adherence to prescribed medication.
Cohero Health Co-founder and CEO Melissa Manice, PhD, MPH, said, "We are enhancing respiratory care by recording critical measurements over time outside of a physician's office. This longitudinal view of changes in lung function over time, in parallel with medication adherence tracking, equips physicians to partner with their patient to make more informed treatment decisions together. We're really excited to be leading a new era of collaborative data driven clinical decisions."
The Cohero Health platform has been deployed in closed pilots in healthcare systems. Early results have shown a 2.5 times increase in medication adherence, and 100% reduction in hospitalizations. The company is expanding to additional pilots ahead of full commercial launch of their full platform later this year.
"The inclusion of a mobile spirometer in our platform allows stakeholders to track, for the first time ever, how patients are using their medication, and how they are responding to their medication, in real-time. Through robust tracking, motivating better behaviors, and early identification of potential acute events, the Cohero Health platform enables better patient management, reduced costs to the healthcare system, and most importantly, healthier patients," said Cohero Health Co-founder and COO, Daniel Weinstein.
Source: Medindia
Advertisement
Cohero Health Co-founder and CEO Melissa Manice, PhD, MPH, said, "We are enhancing respiratory care by recording critical measurements over time outside of a physician's office. This longitudinal view of changes in lung function over time, in parallel with medication adherence tracking, equips physicians to partner with their patient to make more informed treatment decisions together. We're really excited to be leading a new era of collaborative data driven clinical decisions."
The Cohero Health platform has been deployed in closed pilots in healthcare systems. Early results have shown a 2.5 times increase in medication adherence, and 100% reduction in hospitalizations. The company is expanding to additional pilots ahead of full commercial launch of their full platform later this year.
"The inclusion of a mobile spirometer in our platform allows stakeholders to track, for the first time ever, how patients are using their medication, and how they are responding to their medication, in real-time. Through robust tracking, motivating better behaviors, and early identification of potential acute events, the Cohero Health platform enables better patient management, reduced costs to the healthcare system, and most importantly, healthier patients," said Cohero Health Co-founder and COO, Daniel Weinstein.
Source: Medindia
Advertisement
Advertisement
|
Advertisement
Recommended Reading
Latest Medical Gadgets

Scientists have developed an affordable, user-friendly clip that utilizes a smartphone's camera and flash to measure blood pressure at the user's fingertip.

Recent progress in the development of wearable devices has presented alternative ways for sleep monitoring at home, which could be useful in sleep apnea detection.

Researchers develop non-invasive brain imaging techniques to help people with disabilities.

Heart rate notifications and the ECG app on Apple Watch give patients and their clinicians' important information about their heart health.

The new machine learning tool prioritizes driver mutations in brain tumor (glioblastoma) and assists in identifying therapeutic targets.